Key statistics
As of last trade, Inhibikase Therapeutics Inc (IKT:NAQ) traded at 1.19, 50.63% above the 52 week low of 0.79 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.24 |
---|---|
High | 1.24 |
Low | 1.18 |
Bid | 1.19 |
Offer | 1.21 |
Previous close | 1.20 |
Average volume | 24.83k |
---|---|
Shares outstanding | 7.46m |
Free float | 6.57m |
P/E (TTM) | -- |
Market cap | 8.96m USD |
EPS (TTM) | -2.93 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 19:01 BST.
More ▼
Announcements
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
More ▼